uniQure Announces Multiple Presentations at

ByLois C

May 25, 2022 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

LEXINGTON, Mass. and AMSTERDAM, May well 02, 2022 (World NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a primary gene therapy company advancing transformative therapies for sufferers with extreme healthcare requirements, now introduced that 6 knowledge presentations, like 1 oral presentation, will be sent at the American Culture of Gene and Mobile Treatment (ASGCT) Hybrid Congress 2022 Once-a-year Meeting being held May perhaps 16-19 in Washington, D.C.

“Our displays at ASGCT showcase the extraordinary do the job of our uniQure researchers and the breadth of our investigation pipeline as we advance our investigational AAV gene therapy plans,” said Ricardo Dolmetsch, Ph.D. president of investigate and advancement at uniQure. “We are specially proud of our studies demonstrating the likely of the linQURE® cargo system, providing many miRNAs in a one AAV and its application to selectively silence mutant C9orf72 in an ALS preclinical model.”

Certain facts on uniQure’s displays having put at ASGCT incorporate:

  • Title: Alpha-synuclein decreasing and rescue of motor phenotype by miRNA-centered AAV gene remedy in in vivo Parkinson’s sickness models (Summary #19)
    Presenter: Astrid Valles-Sanchez, Ph.D. director of CNS disease biology, uniQure
    Oral Session Title: Oligonucleotide Therapeutics
    Date and Time: Monday, May 16, 11:15 – 11:30 a.m. EDT
  • Title: Building and optimization of novel adeno-involved virus (AAV) rep gene expression regulate system for stable rAAV-packaging insect mobile line (Summary #407)
    Poster Session Title: Vector Products Engineering, Progress or Manufacturing I
    Session Day and Time: Monday, May 16, 5:30 – 6:30 p.m. EDT
  • Title: Useful transfer of engineered microRNAs via extracellular vesicles: An in vitro evidence-of-mechanism study in Huntington’s condition types (Summary #590)
    Poster Session Title: Oligonucleotide Therapeutics II
    Session Date and Time: Tuesday, May 17, 5:30 – 6:30 p.m. EDT
  • Title: Selective silencing of mutant C9orf72 transcripts (Summary #552)
    Poster Session Title: Gene Targeting and Gene Correction II
    Date and Time: Tuesday, Could 17, 5:30 – 6:30 p.m. EDT
  • Title: AAV5-GLA gene remedy outcomes in sustained extensive time period GLA transgene expression and cross correction of focus on organs in Fabry ailment mouse design (Summary #1009)
    Poster Session Title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Illnesses II
    Session Day and Time: Wednesday, May perhaps 18, 5:30 p.m. EDT
  • Title: AAV-mediated APOE gene silencing for Alzheimer’s condition (Abstract #918)
    Poster Session Title: AAV Vectors – Preclinical and Proof-of-principle Studies III
    Day and Time: Wednesday, May 18, 5:30 p.m. EDT

About uniQure
uniQure is providing on the guarantee of gene remedy – single solutions with potentially curative benefits. We are leveraging our modular and validated know-how platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington’s disease, refractory temporal lobe epilepsy, Fabry condition, and other conditions. www.uniQure.com

uniQure Contacts:

By Lois C